- World Pharma News Home » Product » Zevalin® Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment
(a free service delivered by FeedBurner)
Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin® ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma (FL) in Europe. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established. The product would receive marketing authorization for all EU member states as a treatment for this indication later this year upon a favorable review by the European Commission.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments